DepressionNCT02943876
The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes
A study testing personalized depression risk information in people with Depression, run by University of Calgary at 2 sites in Canada.
Trial summary
Major depressive episode (MDE) is one of the most prevalent and disabling form of mental illness in the general population. Despite increased mental health services and antidepressants use in the past 10 years, there has been no measurable change in the prevalence of MDE in the Canadian general population, which… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Depression
- What is being tested?
- personalized depression risk information
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 712 participants
- Where
- 2 sitesCanada
- Study dates
- 1 May 2017to 31 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- did not have a MDE at baseline,
- aged 18+ years old,
- at high risk of MDE based on the algorithms (predicted risk of 6.5%+ for men and of 11.2%+ for women),
- agreement to be contacted for follow-up assessments, and
- no language barriers to English or French.
Who cannot join
- -
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
Mathison Centre for Mental Health Research and Education
Calgary, Alberta, T2N 4Z6
JianLi Wang
Calgary, Alberta, T3A 6B3
About this study
Major depressive episode (MDE) is one of the most prevalent and disabling form of mental illness in the general population. Despite increased mental health services and antidepressants use in the past 10 years, there has been no measurable change in the prevalence of MDE in the Canadian general population, which motivates the search for additional strategies for reducing the burden of MDE. One strategy that has been successful in the fields of oncology, cardiology and diabetes is early identification and prevention - identifying people who are at high risk and taking preventive actions to lower the risk so as to prevent symptoms from progressing into a MDE. As multivariable risk prediction algorithms are used to estimate an individual's risk (probability) of future disease, they can play an important role in the process of early identification. The proposed study stems from a project funded by an operating grant from the Canadian Institutes of Health Research (CIHR). With the CIHR support, the team developed and validated sex-specific prediction algorithms for MDE. As risk prediction is at very early stage in psychiatry and MDE is still highly stigmatized, to facilitate the future implementation of the developed risk prediction algorithms, the proposed study seeks to answer the following research questions: (1) Does disclosure of personalized depression risk information promote high-risk individuals to take preventive actions? (2) Will disclosure of personalized depression risk information negatively affect high-risk people's mental health status in terms of increased psychological distress? To answer the questions, the investigators planned to conduct a randomized controlled trial (RCT) with an embedded qualitative component. The proposed study will develop an evidence base for guiding the disclosure of personalized risk information and understanding the process of risk communication and consumer empowerment, contributing to the advancement of early prevention of MDE in Canada.
Read the detailed description
Rationale: The proposed study stems from a CIHR project and is driven by the results of knowledge translation (KT) activities. The investigators developed the first sex-specific risk prediction models for major depressive episode (MDE) using data from over 10,000 Canadians. The models include age, personal and family history of MDE, childhood trauma, and predictors that may change over time. Using the models, individuals can answer the question: what is my risk of having a MDE in the next 4 years? Knowing this personalized risk information may assist health professionals in communicating with patients and planning preventive actions; disclosing the information may also empower consumers to actively engage in self-help. In the past 5 years, the KT activities with over 500 stakeholders informed that the investigators need to clearly delineate the benefits (enhanced risk perceptions and self-help) and potential risk (increased psychological distress and impaired function) of disclosing the information before implementing the tools.
The goal of this study is to produce evidence about the benefits and potential risks associated with risk disclosure (i.e., the expected outputs). The primary objectives are to compare those who do and do not receive personalized depression risk information in (1) accuracy of risk perceptions, the use of self-help strategies, and (2) changes in psychological distress and functional measures over one year among those who are at high risk of MDE. The secondary objective is to examine the differential impacts of the disclosure on the outcomes by demographics and levels of baseline risk. To achieve these objectives, the investigators propose a 3-year randomized controlled trial (RCT) with an embedded qualitative component.
The proposed study will be a RCT with an embedded qualitative component. The RCT will have one interventional arm (receiving personalized depression risk information) and one control arm. The personalized depression risk will be generated using the sex-specific prediction algorithms for MDE that we developed in Canadians aged 18+ years old. Because the prediction algorithms are sex-specific, the investigators propose to recruit 350 men and 350 women at baseline. After baseline assessment for eligibility, participants will be randomized into intervention and control groups, in men and women separately. To obtain in-depth information about how the personalized depression risk information is processed by participants and how the information affects them emotionally, the research team will conduct qualitative interviews 1 month after the personalized risk information is disclosed. To understand how the personalized risk information affect participants' health behaviors, the investigators will conduct another round of qualitative interviews at 12-month.
Recruitment: The target population of future preventive studies are high risk individuals in the general population, who reside in different regions across the country. For the proposed study, a feasible approach for recruiting eligible participants is the random digit dialing method (RDD). In the past 10 years, we have used the RDD for recruitment in CIHR-funded longitudinal studies and an ongoing national RCT funded by the Movember Foundation. Recruitment, screening and baseline assessment will be done by a telephone interview firm identified through a competitive bidding process.
A random sample of land line and cell phone numbers will be selected. When a household is reached, the person who is 18+ years will be assessed for eligibility. If a household has 2+ persons aged 18+ years, one will be randomly selected. The interviewers will explain the study objectives and procedures and answer questions. Potential participants will be ensured about confidentiality, that participation is voluntary and that they may withdraw at any time. Oral consent will be obtained before assessment of eligibility. Outcome measures will be assessed at baseline, 6 and 12-month.
Baseline Assessment and Randomization Screening: Once a potentially eligible participant is identified, the interviewer will confirm the participant's age and administer the World Health Organization's Composite International Diagnostic Interview - Short Form for Major Depression (CIDI-SFMD) and the sex-specific prediction algorithms. Interviewees who are in a MDE or are below the risk thresholds based on the risk calculators, will be excluded. Individuals with MDE will be encouraged to contact family doctors and information about local mental health resources will be provided. For those who are at low risk, the web site of the sex-specific risk prediction algorithms (www.predictingdepression.com) will be provided so they may monitor their risk in the future.
Baseline assessment: In eligible participants, the interviewer will administer the Non-specific Psychological Distress Scale (K10), Self-help Strategy Use Scale (SSUS), and ask questions about absenteeism and perceived risk of MDE. Our pilot study showed that the screening and baseline assessment take 20 to 25 minutes.
Randomization will be carried out in men and in women separately. Eligible participants who complete the baseline telephone interview will be randomized into intervention and control groups. The randomization will be conducted and managed by the project coordinator affiliated with the project. 350 random numbers (between 0 and 1) will first be generated for men and women separately using Excel ("RAND()") for 350 study identification numbers (ID), ranging from 1 to 350. The 350 random numbers will then be sorted at the descending order and categorized into 2 equal groups:
- the ID numbers in the first group (n = 175) will be allocated to the control group
- the ID numbers in the second group (n = 175) will be allocated to the intervention group
Intervention and Control: For the participants in the intervention group, the personalized risk will be disclosed and the interviewer will inform them that they will be contacted again at 6 months and 12 months. The interest in receiving such personalized depression information has been confirmed by our recent pilot study using the same sampling method. The team's pilot data (n = 200) showed that 100% of high-risk individuals were interested in knowing their risks. Participants in the intervention group will also be informed that some may be contacted in one month for a 30-minute qualitative interview. A package including the following materials will be mailed to intervention participants: (1) thank-you letter, (2) a website containing general information about MDE, and self-help strategies. (3) $20 incentive as appreciation of their participation. For participants in the control group, the project coordinator will inform them that they will be contacted again at 6 and 12 months. Their personal risks will be provided at the 12-month interview. The control group participants will receive the same package as those in the intervention group.
Blinding and follow-up assessments: The telephone interviewers will securely transfer encrypted baseline data to the PI on a bi-weekly basis. The group assignment data will be transferred in a separate file. The follow-up assessments will be conducted at the telephone interview laboratory at the Mathison Mental Health Research \& Education Center. One month before the scheduled follow-up interviews, letters will be sent to participants to remind them of the upcoming interview. After the 12-month interview, participants' group status will be linked with interview data by study ID numbers.
Over the study period, investigators will be blinded to participants' group status. The interviewers who conduct randomization, will not be involved in follow-up interviews. The interviewers who conduct the follow-up interviews in Calgary will not have access to participants' group status. Given the description of study objectives, participants may know their group status. Therefore, it is possible that some participants in the control group may try to find more information about personalized depression risk. At the follow-up assessments, the research staff will ask if they have used any risk prediction tools over the study period. At the follow-up assessments, if participants develop a MDE, they will be encouraged to contact family doctors and information about local mental health resources will be provided.
Qualitative Interviews: To obtain in-depth information about how disclosing personalized depression risk affects participants' decision processes, mental health and health behaviors, the investigators will conduct two rounds of qualitative interviews via telephone, 1 month after these participants receive the personalized depression risk and at 12 months. Each will include a initial random sub-sample of 20 men and 20 women from the intervention group. The qualitative interviews strengthen this study as the researchers will use the findings to "triangulate" our quantitative results and to guide interpretation of the quantitative results. The interviews will be audio recorded. Qualitative interviews will be transcribed verbatim then analyzed inductively for themes. As per Berg themes will be chosen to "reflect all relevant aspects of the messages." The analysis will follow the interpretive practices of constant comparison and attempt to uncover patterns both within and between interviews. Nvivo 10 software will be used to support thematic analysis. It is expected to achieve theoretical saturation with the initial sample. However, if new themes continue to emerge in final interviews, more interviews will be conducted until no new themes emerge.
Risk and mitigation: The investigators acknowledge concerns about the changes in response rates in telephone surveys due to cell phone use and telemarketing. Including eligible participants across the country will enhance the generalizability of the study. Given the vast geographic area of Canada, RDD is the only feasible method. The goal of this study is to recruit participants for a RCT, rather than selecting a representative sample. In a RCT, selection bias is not a serious concern as long as the bias is the same across the intervention and control groups. To mitigate the risk, the interviewers will also access the validated cellphone database. However the use of cellphone numbers is associated with increased costs. Another potential risk of the proposed study is attrition which may incur selection bias. The population-based cohort studies on mental disorders in the workplace, conducted in our lab, showed that we could achieve 77% response rate at one year follow-up without any financial incentives. The strategies for reducing attrition will include appropriately designed introductory scripts, a minimum of nine call back attempts spaced over weekdays and times of day and provision of $20 incentive for each completed interview. Finally, those deemed low risk but who go on to develop MDE will be excluded from the RCT at the screening stage, which is a limitation. the investigators have planned to provide the risk prediction algorithms so that they can monitor their risks in the future.
- Conditions
- Depression
- Being tested
- personalized depression risk information
- Keywords
- risk prediction, risk score, accuracy of risk perception, self-help, psychological distress
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
personalized depression risk informationOther
The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Serves as a control group, receiving generic information about depression and self-help. |
| Intervention | Experimental | Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help. Receives: Other: personalized depression risk information |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in psychological distress
Psychological distress will be measured by the Non-Specific Psychological Distress (K10), a 10-item screening scale intended to yield a global measure of distress based on questions about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period.
Measured: baseline, 6-month, 12-month
Secondary outcomes (2)
Change in self-management strategy use
It will be measured by self-management strategy use scale (SSUS) was developed and validated by Morgan and Jorm
Measured: Baseline, 6-month, 12-month
Accuracy of risk perception
"How likely are you to get depression in the next 4 years?" The answer can range from 0 to 100, where 0=certain not to happen and 100=certain to happen
Measured: baseline, 6- and 12-month follow-up assessment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2016 (estimated)
- Study start1 May 2017
- Primary completion1 May 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for DepressionStudies of the same condition, open and under way.
- More trials run by University of CalgaryThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 712 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Principal investigator, JianLi Wang, University of Calgary
- Investigators
- JianLi Wang, PhD, Principal investigator, University of Calgary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02943876
- Sponsor's protocol ID
- 10015082
- Status last verified
- May 2021
- First submitted
- 21 Oct 2016
- Last updated
- 5 May 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Wang J, Eccles H, Nannarone M, Schmitz N, Patten S, Lashewicz B. Does providing personalized depression risk information lead to increased psychological distress and functional impairment? Results from a mixed-methods randomized controlled trial. Psychol Med. 2022 Aug;52(11):2071-2079. doi: 10.1017/S0033291720003955. Epub 2020 Nov 4.
PubMed 33143794Warner E, Nannarone M, Smail-Crevier R, Manuel D, Lashewicz B, Patten S, Schmitz N, MacQueen G, Wang JL. The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. BMC Public Health. 2020 Jun 6;20(1):876. doi: 10.1186/s12889-020-08983-0.
PubMed 32505198Wang J, MacQueen G, Patten S, Manuel D, Lashewicz B, Schmitz N. A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry. 2019 Sep 18;19(1):285. doi: 10.1186/s12888-019-2270-9.
PubMed 31533691
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes
- ClinicalTrials.gov ID
- NCT02943876
- Acronym / sponsor ID
- 10015082
- Conditions
- Depression
- Keywords
- risk prediction, risk score, accuracy of risk perception, self-help, psychological distress
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 712 participants (actual)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- 1 May 2017 (actual)
- Primary completion
- 1 May 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 25 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Major depressive episode (MDE) is one of the most prevalent and disabling form of mental illness in the general population. Despite increased mental health services and antidepressants use in the past 10 years, there has been no measurable change in the prevalence of MDE in the Canadian general population, which motivates the search for additional strategies for reducing the burden of MDE. One strategy that has been successful in the fields of oncology, cardiology and diabetes is early identification and prevention - identifying people who are at high risk and taking preventive actions to lower the risk so as to prevent symptoms from progressing into a MDE. As multivariable risk prediction algorithms are used to estimate an individual's risk (probability) of future disease, they can play an important role in the process of early identification. The proposed study stems from a project funded by an operating grant from the Canadian Institutes of Health Research (CIHR). With the CIHR support, the team developed and validated sex-specific prediction algorithms for MDE. As risk prediction is at very early stage in psychiatry and MDE is still highly stigmatized, to facilitate the future implementation of the developed risk prediction algorithms, the proposed study seeks to answer the following research questions: (1) Does disclosure of personalized depression risk information promote high-risk individuals to take preventive actions? (2) Will disclosure of personalized depression risk information negatively affect high-risk people's mental health status in terms of increased psychological distress? To answer the questions, the investigators planned to conduct a randomized controlled trial (RCT) with an embedded qualitative component. The proposed study will develop an evidence base for guiding the disclosure of personalized risk information and understanding the process of risk communication and consumer empowerment, contributing to the advancement of early prevention of MDE in Canada.
Detailed description
Rationale: The proposed study stems from a CIHR project and is driven by the results of knowledge translation (KT) activities. The investigators developed the first sex-specific risk prediction models for major depressive episode (MDE) using data from over 10,000 Canadians. The models include age, personal and family history of MDE, childhood trauma, and predictors that may change over time. Using the models, individuals can answer the question: what is my risk of having a MDE in the next 4 years? Knowing this personalized risk information may assist health professionals in communicating with patients and planning preventive actions; disclosing the information may also empower consumers to actively engage in self-help. In the past 5 years, the KT activities with over 500 stakeholders informed that the investigators need to clearly delineate the benefits (enhanced risk perceptions and self-help) and potential risk (increased psychological distress and impaired function) of disclosing the information before implementing the tools.
The goal of this study is to produce evidence about the benefits and potential risks associated with risk disclosure (i.e., the expected outputs). The primary objectives are to compare those who do and do not receive personalized depression risk information in (1) accuracy of risk perceptions, the use of self-help strategies, and (2) changes in psychological distress and functional measures over one year among those who are at high risk of MDE. The secondary objective is to examine the differential impacts of the disclosure on the outcomes by demographics and levels of baseline risk. To achieve these objectives, the investigators propose a 3-year randomized controlled trial (RCT) with an embedded qualitative component.
The proposed study will be a RCT with an embedded qualitative component. The RCT will have one interventional arm (receiving personalized depression risk information) and one control arm. The personalized depression risk will be generated using the sex-specific prediction algorithms for MDE that we developed in Canadians aged 18+ years old. Because the prediction algorithms are sex-specific, the investigators propose to recruit 350 men and 350 women at baseline. After baseline assessment for eligibility, participants will be randomized into intervention and control groups, in men and women separately. To obtain in-depth information about how the personalized depression risk information is processed by participants and how the information affects them emotionally, the research team will conduct qualitative interviews 1 month after the personalized risk information is disclosed. To understand how the personalized risk information affect participants' health behaviors, the investigators will conduct another round of qualitative interviews at 12-month.
Recruitment: The target population of future preventive studies are high risk individuals in the general population, who reside in different regions across the country. For the proposed study, a feasible approach for recruiting eligible participants is the random digit dialing method (RDD). In the past 10 years, we have used the RDD for recruitment in CIHR-funded longitudinal studies and an ongoing national RCT funded by the Movember Foundation. Recruitment, screening and baseline assessment will be done by a telephone interview firm identified through a competitive bidding process.
A random sample of land line and cell phone numbers will be selected. When a household is reached, the person who is 18+ years will be assessed for eligibility. If a household has 2+ persons aged 18+ years, one will be randomly selected. The interviewers will explain the study objectives and procedures and answer questions. Potential participants will be ensured about confidentiality, that participation is voluntary and that they may withdraw at any time. Oral consent will be obtained before assessment of eligibility. Outcome measures will be assessed at baseline, 6 and 12-month.
Baseline Assessment and Randomization Screening: Once a potentially eligible participant is identified, the interviewer will confirm the participant's age and administer the World Health Organization's Composite International Diagnostic Interview - Short Form for Major Depression (CIDI-SFMD) and the sex-specific prediction algorithms. Interviewees who are in a MDE or are below the risk thresholds based on the risk calculators, will be excluded. Individuals with MDE will be encouraged to contact family doctors and information about local mental health resources will be provided. For those who are at low risk, the web site of the sex-specific risk prediction algorithms (www.predictingdepression.com) will be provided so they may monitor their risk in the future.
Baseline assessment: In eligible participants, the interviewer will administer the Non-specific Psychological Distress Scale (K10), Self-help Strategy Use Scale (SSUS), and ask questions about absenteeism and perceived risk of MDE. Our pilot study showed that the screening and baseline assessment take 20 to 25 minutes.
Randomization will be carried out in men and in women separately. Eligible participants who complete the baseline telephone interview will be randomized into intervention and control groups. The randomization will be conducted and managed by the project coordinator affiliated with the project. 350 random numbers (between 0 and 1) will first be generated for men and women separately using Excel ("RAND()") for 350 study identification numbers (ID), ranging from 1 to 350. The 350 random numbers will then be sorted at the descending order and categorized into 2 equal groups:
- the ID numbers in the first group (n = 175) will be allocated to the control group
- the ID numbers in the second group (n = 175) will be allocated to the intervention group
Intervention and Control: For the participants in the intervention group, the personalized risk will be disclosed and the interviewer will inform them that they will be contacted again at 6 months and 12 months. The interest in receiving such personalized depression information has been confirmed by our recent pilot study using the same sampling method. The team's pilot data (n = 200) showed that 100% of high-risk individuals were interested in knowing their risks. Participants in the intervention group will also be informed that some may be contacted in one month for a 30-minute qualitative interview. A package including the following materials will be mailed to intervention participants: (1) thank-you letter, (2) a website containing general information about MDE, and self-help strategies. (3) $20 incentive as appreciation of their participation. For participants in the control group, the project coordinator will inform them that they will be contacted again at 6 and 12 months. Their personal risks will be provided at the 12-month interview. The control group participants will receive the same package as those in the intervention group.
Blinding and follow-up assessments: The telephone interviewers will securely transfer encrypted baseline data to the PI on a bi-weekly basis. The group assignment data will be transferred in a separate file. The follow-up assessments will be conducted at the telephone interview laboratory at the Mathison Mental Health Research \& Education Center. One month before the scheduled follow-up interviews, letters will be sent to participants to remind them of the upcoming interview. After the 12-month interview, participants' group status will be linked with interview data by study ID numbers.
Over the study period, investigators will be blinded to participants' group status. The interviewers who conduct randomization, will not be involved in follow-up interviews. The interviewers who conduct the follow-up interviews in Calgary will not have access to participants' group status. Given the description of study objectives, participants may know their group status. Therefore, it is possible that some participants in the control group may try to find more information about personalized depression risk. At the follow-up assessments, the research staff will ask if they have used any risk prediction tools over the study period. At the follow-up assessments, if participants develop a MDE, they will be encouraged to contact family doctors and information about local mental health resources will be provided.
Qualitative Interviews: To obtain in-depth information about how disclosing personalized depression risk affects participants' decision processes, mental health and health behaviors, the investigators will conduct two rounds of qualitative interviews via telephone, 1 month after these participants receive the personalized depression risk and at 12 months. Each will include a initial random sub-sample of 20 men and 20 women from the intervention group. The qualitative interviews strengthen this study as the researchers will use the findings to "triangulate" our quantitative results and to guide interpretation of the quantitative results. The interviews will be audio recorded. Qualitative interviews will be transcribed verbatim then analyzed inductively for themes. As per Berg themes will be chosen to "reflect all relevant aspects of the messages." The analysis will follow the interpretive practices of constant comparison and attempt to uncover patterns both within and between interviews. Nvivo 10 software will be used to support thematic analysis. It is expected to achieve theoretical saturation with the initial sample. However, if new themes continue to emerge in final interviews, more interviews will be conducted until no new themes emerge.
Risk and mitigation: The investigators acknowledge concerns about the changes in response rates in telephone surveys due to cell phone use and telemarketing. Including eligible participants across the country will enhance the generalizability of the study. Given the vast geographic area of Canada, RDD is the only feasible method. The goal of this study is to recruit participants for a RCT, rather than selecting a representative sample. In a RCT, selection bias is not a serious concern as long as the bias is the same across the intervention and control groups. To mitigate the risk, the interviewers will also access the validated cellphone database. However the use of cellphone numbers is associated with increased costs. Another potential risk of the proposed study is attrition which may incur selection bias. The population-based cohort studies on mental disorders in the workplace, conducted in our lab, showed that we could achieve 77% response rate at one year follow-up without any financial incentives. The strategies for reducing attrition will include appropriately designed introductory scripts, a minimum of nine call back attempts spaced over weekdays and times of day and provision of $20 incentive for each completed interview. Finally, those deemed low risk but who go on to develop MDE will be excluded from the RCT at the screening stage, which is a limitation. the investigators have planned to provide the risk prediction algorithms so that they can monitor their risks in the future.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Serves as a control group, receiving generic information about depression and self-help. |
| Intervention | Experimental | Other: personalized depression risk informationServes as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- did not have a MDE at baseline,
- aged 18+ years old,
- at high risk of MDE based on the algorithms (predicted risk of 6.5%+ for men and of 11.2%+ for women),
- agreement to be contacted for follow-up assessments, and
- no language barriers to English or French.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| personalized depression risk informationThe personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years. | Other | Intervention |
Primary outcome
Change in psychological distress
Time frame: baseline, 6-month, 12-month
Psychological distress will be measured by the Non-Specific Psychological Distress (K10), a 10-item screening scale intended to yield a global measure of distress based on questions about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period.
2 secondary outcomes
Change in self-management strategy use
Time frame: Baseline, 6-month, 12-month
Accuracy of risk perception
Time frame: baseline, 6- and 12-month follow-up assessment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2021.
- Derived from this study: PubMed 33143794Wang J, Eccles H, Nannarone M, Schmitz N, Patten S, Lashewicz B. Does providing personalized depression risk information lead to increased psychological distress and functional impairment? Results from a mixed-methods randomized controlled trial. Psychol Med. 2022 Aug;52(11):2071-2079. doi: 10.1017/S0033291720003955. Epub 2020 Nov 4.
- Derived from this study: PubMed 32505198Warner E, Nannarone M, Smail-Crevier R, Manuel D, Lashewicz B, Patten S, Schmitz N, MacQueen G, Wang JL. The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. BMC Public Health. 2020 Jun 6;20(1):876. doi: 10.1186/s12889-020-08983-0.
- Derived from this study: PubMed 31533691Wang J, MacQueen G, Patten S, Manuel D, Lashewicz B, Schmitz N. A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry. 2019 Sep 18;19(1):285. doi: 10.1186/s12888-019-2270-9.
- Individual participant dataSharing planned: Undecided
Related trials for Depression
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
JianLi Wang, PhD principal investigator
University of Calgary
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing personalized depression risk information in people with Depression, run by University of Calgary at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in psychological distress (time frame: baseline, 6-month, 12-month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02943876, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.